Keenova Therapeutics plc announced the publication of a new manuscript examining whether baseline penile pain influences treatment outcomes in men with Peyronie’s disease treated with Xiaflex (collagenase clostridium… read more.
A multi-institutional research team led by Central South University (CSU) and The Chinese University of Hong Kong (CUHK) has unveiled the most comprehensive genomic analysis to date of… read more.
There has been a lot of discussion about how the age at menopause can affect menopause symptoms. A new study compared the prevalence and severity of menopause symptoms… read more.
AstraZeneca’s Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve, high-risk… read more.
Pfizer announced detailed results from the pivotal Phase 3 TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway… read more.
BD (Becton, Dickinson and Company) announced the introduction of the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete BD’s kidney stone care portfolio… read more.
Reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections, a new study has found. Thousands of… read more.
Blood tests to detect potential signs of prostate cancer likely reduce the risk of dying from prostate cancer, an updated Cochrane review finds. This is a shift from… read more.
ImmunityBio announced results from two indirect treatment comparison (ITC) analyses presented at the 2026 American Urological Association (AUA) Annual Meeting evaluating nogapendekin alfa inbakicept-pmln (NAI, Anktiva) plus Bacillus Calmette–Guérin (BCG)… read more.
Pfizer Inc. announced positive topline results from the Phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an… read more.
The EMA’s CHMP adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Adstiladrin. Since Adstiladrin is an advanced therapy medicinal product, the… read more.
Colorectal cancer (CRC) is the second most common cause of cancer death in the United States and disproportionally impacts people who receive care in under-resourced settings. Fortunately, several… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
